povetacicept

An affinity-optimized Fc fusion protein composed of an engineered variant domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; TNF receptor superfamily 13B; transmembrane activator and CAML interactor; transmembrane activator and calcium modulator and cyclophilin ligand interactor; TACI) fused to a human immunoglobulin (Ig) fragment crystallizable (Fc) domain, with potential immunomodulating activity. Upon administration, povetacicept targets, binds to and inhibits both a proliferation-inducing ligand (tumor necrosis factor ligand superfamily member 13; TNFSF13; APRIL; TNF superfamily 13) and B-cell activating factor (tumor necrosis factor ligand superfamily member 13B; TNFSF13B; BAFF; BlyS; TNF superfamily 13B). This inhibits their interaction with their cell membrane receptors, including TACI, B-cell maturation antigen (tumor necrosis factor receptor superfamily member 17; TNF receptor superfamily 17; TNFRSF17; BCMA) and B cell-expressed BAFF receptor (tumor necrosis factor receptor superfamily member 13C; TNFRSF13C; BAFF-R). This inhibits B-cell proliferation and maturation, immunoglobulin (Ig) secretion, and survival. By inhibiting the production of autoantibodies, povetacicept inhibits B-cell mediated autoimmune responses. Dysregulated APRIL/ and BAFF signaling is implicated in the pathogenesis of multiple autoimmune diseases.